Dasom Son
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dasom Son has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Hokyou Lee
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
6 shared publications - Hyeon Chang Kim
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
6 shared publications - Hyeok-Hee Lee
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
5 shared publications - Jong Hyun Jhee
Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
4 shared publications - Eunji Kim
Department of Preventive Medicine, Gachon University College of Medicine , Incheon
3 shared publications - Jaeyong Lee
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Systematic Review of Cardiovascular Risk Prediction Models for the Korean Population
Lee J, et al. Korean Circ J. 2027 ;57:e33. https://doi.org/10.4070/kcj.2026.0084
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessSystematic Review of Cardiovascular Risk Prediction Models for the Korean Population
Lee J, et al. Korean Circ J. 2027 ;57:e33. https://doi.org/10.4070/kcj.2026.0084
- 25 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Cardiovascular health by Life’s Essential 8 and chronic kidney disease: Korea National Health and Nutrition Examination Survey 2019–2021
Evidence remains limited regarding the association between cardiovascular health (CVH), as defined by Life's Essential 8 (LE8), and chronic kidney disease (CKD), particularly across its indicators and stages. We analyzed data from 12,264 adults in the Korea National Health and Nutrition Examination Survey (2019-2021). LE8 scores (range, 0-100), calculated from eight components-diet, physical activity, nicotine exposure, sleep, body mass index, blood lipids, blood glucose, and blood pressure, were analyzed as both continuous and categorical variables: low (0 to <50), moderate (50 to <80), and high CVH (80 to 100). CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g). Multivariable logistic regression and restricted cubic spline models were used to examine associations between LE8 scores and CKD, with stratification by CKD indicators and by G and A stages. Overall, 13.3% of participants were classified as having low CVH, 75.4% as moderate CVH, and 11.3% as high CVH. Compared to low CVH, the odds of CKD were lower in moderate CVH (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.33-0.46) and high CVH (OR, 0.22; 95% CI, 0.15-0.33). Each 10-point higher CVH score was associated with 33% lower odds of CKD (OR, 0.67; 95% CI, 0.63-0.71). After stratifying decreased eGFR and albuminuria by G and A stages, higher CVH was consistently associated with lower odds of CKD, even for early stages. Higher LE8 scores were inversely associated with CKD and its indicators, including early-stage CKD.
- 25 March 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Cardiovascular health by Life’s Essential 8 and chronic kidney disease: Korea National Health and Nutrition Examination Survey 2019–2021
Evidence remains limited regarding the association between cardiovascular health (CVH), as defined by Life's Essential 8 (LE8), and chronic kidney disease (CKD), particularly across its indicators and stages. We analyzed data from 12,264 adults in the Korea National Health and Nutrition Examination Survey (2019-2021). LE8 scores (range, 0-100), calculated from eight components-diet, physical activity, nicotine exposure, sleep, body mass index, blood lipids, blood glucose, and blood pressure, were analyzed as both continuous and categorical variables: low (0 to <50), moderate (50 to <80), and high CVH (80 to 100). CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g). Multivariable logistic regression and restricted cubic spline models were used to examine associations between LE8 scores and CKD, with stratification by CKD indicators and by G and A stages. Overall, 13.3% of participants were classified as having low CVH, 75.4% as moderate CVH, and 11.3% as high CVH. Compared to low CVH, the odds of CKD were lower in moderate CVH (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.33-0.46) and high CVH (OR, 0.22; 95% CI, 0.15-0.33). Each 10-point higher CVH score was associated with 33% lower odds of CKD (OR, 0.67; 95% CI, 0.63-0.71). After stratifying decreased eGFR and albuminuria by G and A stages, higher CVH was consistently associated with lower odds of CKD, even for early stages. Higher LE8 scores were inversely associated with CKD and its indicators, including early-stage CKD.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1) , e13
Korea Hypertension Fact Sheet 2025: national trends in hypertension with a special analysis of hypertensive disorders of pregnancy
Kim HC, et al. Clin Hypertens. 2026 ;32(1):e13. https://doi.org/10.5646/ch.2026.32.e13
- 1 January 2026
- Published by XMLink in Clinical Hypertension
- Vol. 32 (1) , e13
Top Cited PapersOpen AccessKorea Hypertension Fact Sheet 2025: national trends in hypertension with a special analysis of hypertensive disorders of pregnancy
Kim HC, et al. Clin Hypertens. 2026 ;32(1):e13. https://doi.org/10.5646/ch.2026.32.e13
- Open Access
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19) , e042966
Blood Pressure and Cardiovascular Outcomes in Adults With Diabetes and Chronic Kidney Disease
Background: Current hypertension guidelines recommend intensive blood pressure (BP) targets (eg, <130/80 mm Hg) for patients with diabetes and chronic kidney disease. However, data supporting these recommendations are limited. Methods: From Korean nationwide health screening and claims data, we identified 373 966 adults with both diabetes and chronic kidney disease who (1) underwent a baseline health examination in 2009 to 2013; (2) had ≥3 BP‐measuring visits during a 5‐year look‐back period; and (3) did not have prior cardiovascular disease (CVD). The mean of all BPs measured throughout the look‐back period was used for the analysis. The primary outcome was CVD event, defined as a composite of myocardial infarction, stroke, heart failure, or death from CVD. Results: Over a median follow‐up of 10.2 years, 40 781 CVD events occurred. When using systolic BP 130 to <140 mm Hg as the reference, multivariable‐adjusted hazard ratios (HRs) for CVD event in the systolic BP ≥150, 140 to <150, 120 to <130, and <120 mm Hg groups were 1.34 (95% CI, 1.29–1.39), 1.11 (95% CI, 1.08–1.14), 0.89 (95% CI, 0.87–0.91), and 0.77 (95% CI, 0.74–0.80), respectively. When using diastolic BP 80 to <90 mm Hg as the reference, HRs in the diastolic BP ≥100, 90 to <100, 70 to <80, and <70 mm Hg groups were 1.70 (95% CI, 1.56–1.85), 1.19 (95% CI, 1.15–1.24), 0.88 (95% CI, 0.86–0.90), and 0.83 (95% CI, 0.80–0.87), respectively. Systolic BP <130 mm Hg and diastolic BP <80 mm Hg were each associated with reduced CVD risk in a log‐linear pattern. Conclusions: Among patients with diabetes and chronic kidney disease, SBP <130 mm Hg and diastolic BP <80 mm Hg were associated with reduced risk of CVD.
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19) , e042966
Open AccessBlood Pressure and Cardiovascular Outcomes in Adults With Diabetes and Chronic Kidney Disease
Background: Current hypertension guidelines recommend intensive blood pressure (BP) targets (eg, <130/80 mm Hg) for patients with diabetes and chronic kidney disease. However, data supporting these recommendations are limited. Methods: From Korean nationwide health screening and claims data, we identified 373 966 adults with both diabetes and chronic kidney disease who (1) underwent a baseline health examination in 2009 to 2013; (2) had ≥3 BP‐measuring visits during a 5‐year look‐back period; and (3) did not have prior cardiovascular disease (CVD). The mean of all BPs measured throughout the look‐back period was used for the analysis. The primary outcome was CVD event, defined as a composite of myocardial infarction, stroke, heart failure, or death from CVD. Results: Over a median follow‐up of 10.2 years, 40 781 CVD events occurred. When using systolic BP 130 to <140 mm Hg as the reference, multivariable‐adjusted hazard ratios (HRs) for CVD event in the systolic BP ≥150, 140 to <150, 120 to <130, and <120 mm Hg groups were 1.34 (95% CI, 1.29–1.39), 1.11 (95% CI, 1.08–1.14), 0.89 (95% CI, 0.87–0.91), and 0.77 (95% CI, 0.74–0.80), respectively. When using diastolic BP 80 to <90 mm Hg as the reference, HRs in the diastolic BP ≥100, 90 to <100, 70 to <80, and <70 mm Hg groups were 1.70 (95% CI, 1.56–1.85), 1.19 (95% CI, 1.15–1.24), 0.88 (95% CI, 0.86–0.90), and 0.83 (95% CI, 0.80–0.87), respectively. Systolic BP <130 mm Hg and diastolic BP <80 mm Hg were each associated with reduced CVD risk in a log‐linear pattern. Conclusions: Among patients with diabetes and chronic kidney disease, SBP <130 mm Hg and diastolic BP <80 mm Hg were associated with reduced risk of CVD.
- Top Cited PapersOpen Access
- 1 January 2025
- Published by XMLink in Clinical Hypertension
- Vol. 31 (1) , e11
Korea Hypertension Fact Sheet 2024: nationwide population-based analysis with a focus on young adults
Kim HC, et al. Clin Hypertens. 2025 Mar;31(1):e11. https://doi.org/10.5646/ch.2025.31.e11
- 1 January 2025
- Published by XMLink in Clinical Hypertension
- Vol. 31 (1) , e11
Top Cited PapersOpen AccessKorea Hypertension Fact Sheet 2024: nationwide population-based analysis with a focus on young adults
Kim HC, et al. Clin Hypertens. 2025 Mar;31(1):e11. https://doi.org/10.5646/ch.2025.31.e11
- Top Cited PapersOpen Access
- 1 January 2024
- Published by XMLink in Clinical Hypertension
- Vol. 30 (1) , 1-11
Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations
The Korea Hypertension Fact Sheet 2023, presented by the Korean Society of Hypertension, offers an overview of the prevalence and management of hypertension, along with recent trends. Data for the Fact Sheet were derived from the Korea National Health and Nutrition Examination Survey spanning 1998 to 2021, and the National Health Insurance Big Data from 2002 to 2021. As of 2021, hypertension affected 28.0% of Korean adults aged 20 and older, totaling approximately 12.3 million individuals, with 5.3 million (43.5%) aged 65 or older. Among those with hypertension, awareness stood at 74.1%, treatment rates at 70.3%, and control rates at 56.0%. Over the years, the number of hypertension diagnoses increased from 3.0 million in 2002 to 11.1 million in 2021. During the same period, the utilization of antihypertensive medications rose from 2.5 million to 10.5 million, with treatment adherence also improving from 0.6 million to 7.8 million individuals. In 2021, the predominant antihypertensive drug class was angiotensin receptor blockers (75.1%), followed by calcium channel blockers (61.7%), diuretics (23.4%), and beta blockers (15.3%). Notably, 60.2% of all antihypertensive prescriptions involved combination therapy with at least two classes of antihypertensive medication. There was a positive trend towards stricter blood pressure control targets (systolic/diastolic blood pressure < 130/80 mmHg) among elderly hypertensive patients, as well as those with diabetes, obesity, and high-risk hypertension. However, this trend declined in individuals aged 80 years or older and those with chronic kidney disease in recent years. In Korea, hypertension management is making strides, yet the total number of hypertensive individuals is rising. Effectively addressing the growing population of elderly hypertensive patients and the persistently low treatment rates among younger individuals with hypertension is a critical challenge. Additionally, developing more efficient and customized policies for blood pressure control and cardiovascular disease prevention is imperative.
- 1 January 2024
- Published by XMLink in Clinical Hypertension
- Vol. 30 (1) , 1-11
Top Cited PapersOpen AccessKorea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations
The Korea Hypertension Fact Sheet 2023, presented by the Korean Society of Hypertension, offers an overview of the prevalence and management of hypertension, along with recent trends. Data for the Fact Sheet were derived from the Korea National Health and Nutrition Examination Survey spanning 1998 to 2021, and the National Health Insurance Big Data from 2002 to 2021. As of 2021, hypertension affected 28.0% of Korean adults aged 20 and older, totaling approximately 12.3 million individuals, with 5.3 million (43.5%) aged 65 or older. Among those with hypertension, awareness stood at 74.1%, treatment rates at 70.3%, and control rates at 56.0%. Over the years, the number of hypertension diagnoses increased from 3.0 million in 2002 to 11.1 million in 2021. During the same period, the utilization of antihypertensive medications rose from 2.5 million to 10.5 million, with treatment adherence also improving from 0.6 million to 7.8 million individuals. In 2021, the predominant antihypertensive drug class was angiotensin receptor blockers (75.1%), followed by calcium channel blockers (61.7%), diuretics (23.4%), and beta blockers (15.3%). Notably, 60.2% of all antihypertensive prescriptions involved combination therapy with at least two classes of antihypertensive medication. There was a positive trend towards stricter blood pressure control targets (systolic/diastolic blood pressure < 130/80 mmHg) among elderly hypertensive patients, as well as those with diabetes, obesity, and high-risk hypertension. However, this trend declined in individuals aged 80 years or older and those with chronic kidney disease in recent years. In Korea, hypertension management is making strides, yet the total number of hypertensive individuals is rising. Effectively addressing the growing population of elderly hypertensive patients and the persistently low treatment rates among younger individuals with hypertension is a critical challenge. Additionally, developing more efficient and customized policies for blood pressure control and cardiovascular disease prevention is imperative.